汕头大学医学院学报

参考文献

[1]耿研,谢希,王昱,等.类风湿关节炎诊疗规范[J].中华内科杂志, 2022, 61(1):51-59.

[2]KONDO N, KURODA T, KOBAYASHI D. Cytokine networks in the pathogenesis of rheumatoid arthritis[J]. Int J Mol Sci, 2021,22(20):10922.

[3]PARISI S, DITTO M C, GHELLERE F, et al. Update on tocilizumab in rheumatoid arthritis:a narrative review[J]. Front Immunol, 2025, 16:1470488.

[4]KIM M, CHOE Y H, LEE S I. Lessons from the success and failure of targeted drugs for rheumatoid arthritis:perspectives for effective basic and translational research[J]. Immune Netw,2022, 22:e8.

[5]TORNERO MOLINA J, HERNÁNDEZ-CRUZ B, COROMINAS H. Initial treatment with biological therapy in rheumatoid arthritis[J]. J Clin Med, 2024, 13(1):48.

[6]LIU T, WANG L, ZHANG X, et al. Tocilizumab monotherapy or combined with methotrexate for rheumatoid arthritis:a randomized clinical trial[J]. JAMA Netw Open, 2025, 8(5):e2511095.

[7]BURMESTER G R, BUTTGEREIT F, BERNASCONI C, et al.Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis(SEMIRA):a double-blind, multicentre, randomised controlled trial[J]. Lancet, 2020, 396(10246):267-276.

[8]LAEEQ S, REGHEFAOUI T, ZAHOOR H, et al. Effectiveness of biologics and targeted synthetic disease-modifying antirheumatic drugs in conjunction with methotrexate for the treatment of early rheumatoid arthritis:a systematic review of randomized controlled trials[J]. Musculoskelet Care, 2022, 20(3):471-486.

[9]BOUSSAID S, TBINI H, REKIK S, et al. Predictors of drug retention and survival rate of bDMARDs in rheumatoid arthritis:a four-year real-life Tunisian experience[J]. Mediterr J Rheumatol, 2024, 35(3):448.

[10]SINGH S, FUMERY M, SINGH A G, et al. Comparative risk of cardiovascular events with biologic and synthetic diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis:a systematic review and meta-analysis[J]. Arthritis Care Res, 2020, 72(4):561-576.

[11]YIP R M L, YIM C W. Role of interleukin 6 inhibitors in the management of rheumatoid arthritis[J]. J Clin Rheumatol, 2021,27(8):e516-e524.

[12]ZHANG H, WANG H, WEI H J, et al. A phase I clinical study comparing the tolerance, immunogenicity, and pharmacokinetics of proposed biosimilar BAT1806 and reference tocilizumab in healthy Chinese men[J]. Front Pharmacol, 2021, 11:609522.

[13]LENG X M, LESZCZYŃSKI P, JEKA S, et al. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate:a phase 3,randomised, multicentre, double-blind, active-controlled clinical trial[J]. Lancet Rheumatol, 2024, 6(1):e40-e50.

[14]LENG X M, LESZCZYŃSKI P, JEKA S, et al. A phase 3,randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderateto-severe rheumatoid arthritis with inadequate response to methotrexate:treatment period 2 analysis(week 24 to week 48)[J]. Arthritis Res Ther, 2024, 26(1):157.

[15]EBBERS H C, TAYLOR P C, LENG X M, et al. A comparison of the immunogenicity of intravenous BAT1806, a tocilizumab biosimilar, and its reference product[J]. Rheumatol Ther, 2025,12(3):529-546.

[16]METGHALCHI Y, YAGHOUBI N, YOUSEFI N, et al. Costeffectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran[J].Cost Eff Resour Allocation, 2024, 22(1):82.

[17]TAN C Q, LUO X, LI S N, et al. Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China:a costeffectiveness analysis[J]. Clin Rheumatol, 2022, 41(1):63-73.

[18]PÉREZ-RUIZ F, CRESPO-DIZ C, SCHOENENBERGERARNAIZ J A, et al. Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain[J]. Farmacia Hosp, 2025, 49(5):278-285.

[19]DU X, LUO X X, GUO Q X, et al. Assessment of clinical benefit,cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China[J]. Front Public Health, 2024, 12:1476213.

[20]VAN ESVELD L, COX J M, KUIJPER T M, et al. Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands[J]. Ann Rheum Dis, 2023, 82(10):1-11.

[21]方碧陶.国家药品监督管理局印发《真实世界证据支持药物研发与审评的指导原则(试行)》[J].中医药管理杂志, 2020, 28(2):107.